Background {#Sec1}
==========

Major advances have occurred in the diagnosis and classification of spondyloarthritis (SpA) over the last 10 years, especially since spinal inflammation was demonstrated on magnetic resonance imaging (MRI) in the absence of radiographic evidence of change \[[@CR1]\]. The changes were formalized in the revised versions of the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial (ax) \[[@CR2]\] and peripheral SpA \[[@CR3]\]. Thanks to these criteria, patients with axial SpA without radiographic evidence of sacroiliitis can now be classified as having non-radiographic axSpA, a form which does not appear to differ significantly from radiographic axSpA in terms of the main clinical manifestations, disease activity, pain, quality of life and response to anti-tumor necrosis factor (anti-TNF) therapy \[[@CR4]--[@CR6]\]. Differences between patients with non-radiographic and radiographic axSpA have been found in age, symptom duration, human leukocyte antigen (HLA)-B27 positivity \[[@CR7]\] and gender distribution. Although less inflammation (i.e., lower C-reactive protein and less evidence of spinal inflammation on MRI) and less impairment in spinal mobility have been observed in non-radiographic axSpA than in the axSpA, the two conditions are associated with a similar burden in terms of disease activity, physical function and health ratio quality of life (HR-QoL) impairment \[[@CR8]\]. ASAS classification criteria are also important because they enable detection of early SpA, so that treatment can be introduced earlier than in the past when the average delay in diagnosis was about 10 years \[[@CR9]\]. Of course, former classification criteria for specific subtypes of SpA, such as the modified New York Criteria for ankylosing spondylitis (AS) \[[@CR10]\] or Classification Criteria for Psoriatic Arthritis (CASPAR) for psoriatic arthritis (PsA) \[[@CR11]\] remain valid to classify particular forms of the disease.

Before the introduction of the ASAS criteria, the global prevalence of SpA was calculated to be approximately 1 %, with notable variability, ranging from 0.01 % in Japan to 2.5 % in Northern Arctic populations. The recognition of non-radiographic axSpA will have a considerable impact on the prevalence of SpA, because many patients who had an unclassifiable axSpA can now be classified according to the ASAS criteria \[[@CR1], [@CR8]\].

The increase in the prevalence of SpA has notable socioeconomic implications. By definition, SpA is a disease that occurs in young adults at the peak of their productive lifespan \[[@CR2]\]. Moreover, it is associated with a considerable burden in terms of restrictions in activities of daily living \[[@CR12], [@CR13]\], reduction in health-related quality of life (HR-QoL) \[[@CR13], [@CR14]\] and in work productivity, and in terms of unemployment \[[@CR15]--[@CR17]\].

The reduction in work productivity is an important component of the indirect costs of SpA, which are typically calculated in terms of absenteeism and presenteeism using tools such as the Work Productivity and Activity Impairment Questionnaire in AS (WPAI) \[[@CR18]\]. Absenteeism is defined as the quantity of sick leave either specifically due to the disease itself or, in the event that it is difficult to distinguish between sick leave due to the disease itself and sick leave due to concomitant or incident diseases, the total amount of sick leave expressed as days in a year or hours per week. Presenteeism is defined as patient-reported reduced productivity at work \[[@CR18]\]. Caution is required in the extrapolation of data from one country to another, because findings on work productivity and unemployment are affected by a number of local factors, primarily the local unemployment/disability benefit system \[[@CR19]\].

We carried out a survey in Italy called Atlantis (an underwater world that we would like to bring to light), which was designed to establish how the diagnostic work-up and management of SpA in Italy is experienced by the patients, and assess the impact of SpA on daily living, personal relationships, work disability and working life. This paper reports findings on work disability and working life.

Methods {#Sec2}
=======

Study characteristics {#Sec3}
---------------------

This was a cross-sectional survey sponsored by the Italian National Association of Rheumatic Patients (ANMAR). It was carried out in 17 out of the 20 regions in Italy from 1 January to 31 March 2013 by Doxa-Pharma, a company experienced in carrying out surveys in the healthcare field, under the guidance of an experienced rheumatologist (RR, author), who was the scientific coordinator of the project. According to Italian regulations, the study did not require written informed consent because the questionnaire was completed anonymously. Additional sensitive data were not collected.

Patients and methods {#Sec4}
--------------------

The survey was conducted on patients with a defined diagnosis of SpA made by a rheumatologist and the questionnaire was drafted with five sections: (1) personal details and diagnosis of the patient, including information on work status and any welfare benefits granted; (2) the diagnostic work-up; (3) follow up; (4) impact of the disease on quality of life; and (5) impact on working life, including absenteeism and presenteeism. We considered the indirect costs of the disease in terms of sick leave, which was defined as the weekly cost due to the hours of absence from the job because of the disease, and in terms of presenteeism, which was defined as the quantification of the weekly cost due to the lower job performance of the patients because of the disease. The sum of these two indices, termed the time loss, was defined as the weekly income that was not produced (indirect cost), considering the Italian weekly per capita income in euros in 2012 divided by the standard 44 weeks of work. The multiple-choice questions focused on work status and working life (see Additional file [1](#MOESM1){ref-type="media"} for all questions in detail). Data were collected through two parallel channels: (1) the survey questionnaire was published on the web, with a link placed at the official ANMAR website ([www.anmar-italia.it](http://www.anmar-italia.it)), to be completed by patients who were willing to do so, and (2) hard copies of the survey questionnaire were distributed throughout the Italian regions of interest by ANMAR volunteers, with the support of specialists at the hospitals with clinics dedicated to the management of rheumatic patients.

Data analysis {#Sec5}
-------------

The data were analyzed descriptively. For the open questions we read all the answers and encoded various items. Data were expressed in terms of frequency and averages. Electronic software (SAS and DIANA) was used to perform an interpretative reading of these data. Collected data were analyzed in relation to sociodemographic variables (sex, age, area of residence) and the type of specific SpA disease.

Results {#Sec6}
=======

A total of 770 subjects took part in the survey. Their main features are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Main features of survey respondentsSociodemographic characteristicsRespondents, %Gender Male56 % Female44 %Age, years ≤308 % 31--4017 % 41--5026 % 51--6027 % 61--7017 % \>704 % Not specified1 %Education Degree/Master's degree17 % High school45 % Junior high school28 % Primary school8 % Not specified2 %Marital status Married/living with partner64 % Single20 % Divorced/separated/widow(er)12 % Not specified4 %Residence North-West24 % North-East26 % Central regions26 % South and Islands24 %Diagnosis Ankylosing spondylitis41 % Psoriatic arthritis39 % Spondyloartritis with inflammatory bowel disease10 % Undifferentiated spondyloarthritis6 % Reactive arthritis4 %

More respondents were men (56 %). Most of them were married or living with a partner (64 %), were of working age (78 % aged ≤60 years; mean age = 50 years) and educated (62 % had completed high school or had a university degree). Their distribution throughout Italy was homogeneous, ranging from 24--26 % in the four main Italian geographical areas. The subjects were suffering from AS (41 %), PsA (39 %) SpA with inflammatory bowel diseases (IBD) (10 %), undifferentiated SpA (6 %) and reactive arthritis (4 %) (Fig. [1](#Fig1){ref-type="fig"}). Many patients reported that they had contacted other specialists after the diagnosis: ophthalmologists 50 %, cardiologists 45 %, dermatologists 43 %, gastroenterologists 37 %, psychologists 10 %, specialists in infectious diseases 8 %, pulmonologists 2 %, neurologists 2 %, gynecologists 1 %, endocrinologists 1 %, and neurosurgeons 1 % \[[@CR20]\].Fig. 1Main work status in patients with spondyloarthritis

Slightly below half of the respondents were working either full-time (45 %) or part-time (8 %). Nearly one fourth had retired (22 %) and 15 % were unemployed (for reasons linked to SpA in 4 % of the cases; the remaining were students, housewives or individuals who were unemployed due to reasons other than SpA) (Fig. [1](#Fig1){ref-type="fig"}). Half of the respondents (49 %) reported that they were disabled (Table [2](#Tab2){ref-type="table"}) and had to cancel or postpone commitments because of their disease (50 %) and 13 % declared that they had to do this at least half of the time. This depended on symptom control.Table 2Impact on working lifeReported consequences of SpARespondents, %Disability49 % Receives disability benefits34 % Has applied for disability benefits8 % Cannot work full-time, but does not meet criteria for disability benefit7 %Has to cancel or postpone work commitments because of SpA50 % Does not apply27 % Never23 % Sometimes37 % About half the time7 % Most of the time4 % All the time2 %Limitations to work projects or career in general because of SpA48 % Does not apply20 % None12 % Negligible20 % Minor limitations12 % Tangible limitations15 % Major limitations21 %Had to change/leave a job or lost a job because of SpA21 % Yes21 % Does not apply24 % No55 %Has felt discriminated at work because of SpA14 % Yes14 % Does not apply31 % No55 %Fewer raises in salary because of SpA14 % Does not apply44 % Not at all36 % Negligible6 % A little4 % Quite a bit7 % A lot3 %*SpA* spondyloarthritis

One third of patients (36 %) experienced important limitations that hindered their professional development/career. Of these, 19 % had controlled symptoms, 32 % were improving and 50 % had uncontrolled symptoms. One in five patients actually had to change or leave their job or had actually lost it because of SpA (21 %). Discrimination may have played a role in some cases, because 14 % of subjects reported this, and another 14 % believed that SpA had had an impact on their salary (Table [2](#Tab2){ref-type="table"}). The impact on salary also depended on symptom control: 12 % of the patients with controlled symptoms believed that their disease had had a negative effect on their salary compared to 20 % with uncontrolled symptoms. The 383 respondents (49.7 % of the total sample) who were employed had worked on average 32.2 h in the last 7 days. Approximately 60 % had actually worked full-time (31 h or more) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Results (employed/unemployed workers) by the survey

Questions about absenteeism revealed that more hours had been lost over the previous 7 days due to SpA (on average 2.39 h vs 1.67 h), than for other reasons such as vacation or family commitments. The hours of absence because of SpA amounted to 59 % of the hours of absence from the work place and to 7 % of weekly working hours. The time loss cost was €216 per week for the patients reporting permanent impairment and €106 euros for the patients who reported well-being or an improvement in their physical condition.

Discussion {#Sec7}
==========

This survey spearheaded by ANMAR has shown that patients with SpA experience major disadvantages in their working life: one half of the respondents claimed that they were disabled, and one half reported that SpA interfered significantly with their work commitments; SpA was the main source of absenteeism and presenteeism. What is more, the survey identified a number of issues that, to our knowledge, have not been investigated to date: one half experienced restrictions in their work prospects and career, 21 % had had to change/leave a job or had lost a job because of SpA, and 14 % had experienced discrimination at the workplace.

The sample was representative of the SpA population in terms of gender, age and diagnosis, \[[@CR1], [@CR21], [@CR22]\]. Participation from all four main geographical areas of Italy was almost the same for each (24--26 %). The collection of data both via the website and distribution at hospital outpatient clinics ensured that there was no pre-selection of computer-literate patients \[[@CR23]\]. Even so, the survey did include patients who were more educated than average, as only 28 % of respondents had not continued after junior high school, whereas the national average in 2013 was 44 % \[[@CR23]\]; this is probably due to the fact that the elderly (a less educated generation) were under-represented in the sample (patients over 60 years of age represented 21 % vs the 27.2 % in the general population \[[@CR24]\].

The employment rate was slightly lower than in the general population, being 53 % instead of the expected rate of 58 %, according to the official employment statistics in the general population in Italy in 2013 \[[@CR25]\], after correction for the higher percentage of male individuals in the survey than in the general population. Discrimination may have played a role in some cases; in fact, 14 % of the patients reported having the impression of being treated differently from other colleagues due to their rheumatic disease. The proportion of SpA patients receiving disability benefits was nearly five times higher than the proportion in the general population (34 % vs 7.3 %) \[[@CR24], [@CR26]\].

One of our study limitations was the use of a non-validated questionnaire. However, our findings on work disability and reduction in productivity, both in terms of absenteeism and presenteeism, are consistent with similar published studies, which all report that SpA is associated with disability and reduction in productivity. Nevertheless, comparisons between different studies is difficult because of the differences in patient populations (e.g., the proportions with manual vs non-manual occupations, proportions with non-SpA-related comorbidities), and in the definition of endpoints (e.g., sick leave may be total or restricted to leave due to SpA), and, above all, differences in local employment and benefit systems \[[@CR25]\]. The mean total sick leave was 4 hours per week, which amounts to 26 days of sick leave a year, which is well within the range reported in the literature mentioned above.

In our results we also included an assessment of indirect costs, in terms of time loss, which is the sum of sick leave and presenteeism costs. In this study time loss cost was €216 per week for the patients with permanent impairment and €106 euros for the patients who were well or claimed that their physical conditions had improved.

Another limitation of this survey is the lack of information on disease duration. However, it has been shown that productivity is substantially reduced, even in patients with early SpA (mean disease duration 4.8 years) \[[@CR27]\]. This evidence is cause for major concern, because the onset of the disease is in young adulthood and it therefore results in limitations during patients' most productive years. Indeed, this prospect was emphasized by the fact that nearly half of the respondents had the perception of a loss in their work prospects.

To our knowledge, this is the first survey that documents the perception of limitations in work prospects and career, and discrimination at the workplace. A number of factors have been found to be associated with work disability and loss of productivity at work. Unemployment is associated with older age, social deprivation, longer disease duration, functional impairment, and depression, whereas absenteeism is associated only with disease activity and depression, and presenteeism with older age, disease activity, anxiety, and depression \[[@CR28]\]. In particular, in a cross-sectional self-reported postal survey examining 1447 Swedish respondents with SpA, presenteeism was associated with a series of disease activity and quality of life measures, including the Bath Ankylosing Spondylitis Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the EuroQoL (EQ)-5D pain and symptom, and the ASAS scores \[[@CR17]\]. Findings were similar within the more rigorous context of a randomized, controlled clinical trial (ATLAS) in which there was significant correlation between the Short Form (SF)-36/Ankylosing Spondylitis Quality of Life (ASQoL), BASDAI/BASFI,/Health Utility Index (HUI)-3 scores and WPAI-Specific Health Problem (SHP) scores, and between the patient's and the physician's global assessment of disease activity and WPAI-SHP scores \[[@CR29]\]. The correlation between the level of disease activity and work productivity suggests that treatments able to control disease activity would also reduce disability and loss of productivity \[[@CR30]--[@CR34]\].

Conclusions {#Sec8}
===========

As SpA impacts productivity mainly in the prime of patients\' working lives, it is important to increase public awareness, so that patients will be in a position to seek timely, appropriate care, which will undoubtedly optimize their diagnostic and therapeutic outcome.

Additional file {#Sec9}
===============

Additional file 1:Anonymous questionnaire (multiple choice questions). (PDF 56 kb)

ANMAR

:   Italian National Association of Rheumatic Patients

AS

:   ankylosing spondylitis

ASAS

:   Assessment of SpondyloArthritis International Society

ASQoL

:   Ankylosing Spondylitis Quality of Life

Ax

:   axial

BASDAI

:   Bath Ankylosing Spondylitis Activity Index

BASFI

:   Bath Ankylosing Spondylitis Functional Index

EQ-5D

:   EuroQoL-5D

HR-QoL

:   health-related quality of life

HUI-3

:   Health Utility Index scores

IBD

:   inflammatory bowel disease

MRI

:   magnetic resonance imaging

PsA

:   psoriatic arthritis

SF-36

:   Short Form-36

SpA

:   spondyloarthritis

TNF

:   tumor necrosis factor

WPAI

:   Work Productivity and Activity Impairment Questionnaire
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